medigraphic.com
ISSN 1561-302X (Print)

2018, Number 4

<< Back Next >>

Rev cubana med 2018; 57 (4)

Therapeutic evolution of chronic hepatitis C virus

Velbes MPE, Mas MMZ, Nodarse CH

Language: Spanish
References: 38
Page: 1-14
PDF size: 266.84 Kb.


ABSTRACT

Few geographical areas escape the pandemic that represents the viral infection by virus C. The percentage of evolution to chronicity are high. Between 20-30 % develop liver cirrhosis and its complications within 30 years. The foot path traveled in the healthcare practice is reviewed until reaching the era of direct action antivirals, when patients can obtain a substantial eradication of the hepatitis C virus (HCV) with a combination of drugs that raises the rates of sustained virological response (RVS). The eradication of this virus is associated with better quality of life, low morbidity and mortality.


REFERENCES

  1. Mohd HK, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-42.

  2. World Health Organization. Hepatitis C. World Health Organization. 2014[acceso: 22/05/2018]. Disponible en: https://www.who.int/mediacenter/factsheets/fs164/en/

  3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-21.

  4. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87. PubMed: PMID: 25069599

  5. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553-62.

  6. Martell M, Esteban JI, Quer J, Genescà J, Weiner A, Esteban R, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992;66(5):3225-9.

  7. Kumar D, Malik A, Asim M, Chakravarti A, Das RH, Kar P. Influence of quasispecies on virological responses and disease severity in patients with chronic hepatitis C. World J Gastroenterol. 2008;14(5):701-8.

  8. Rodríguez L, Villalba MC, Corredor MB, Frómeta SS, Hernández JM, Carrera SD, et al. HCV genotype determination in monoinfected and HIV co-infected patients in Cuba.Trans R Soc Trop Med Hyg. 2012;106(12):711-7.

  9. Gómez C, Chávez NC, Ponciano G, Uribe M, Méndez N. Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America. Ann Hepatol. 2015;14(6):807-14. PubMed:PMID:26436352

  10. González EE, Marante J, Amador Y, Álvarez L, Guerra I, Martínez G, et al. Analysis of hepatitis C virus core encoding sequences in chronically infected patients reveals mutability, predominance, genetic history and potential impact on therapy of Cuban genotype 1b isolates. Eur Rev Med Pharmacol Sci. 2011;15(11):1320-7.

  11. Wedemeyer H. Fisiopatología diagnóstico y tratamiento. En: Feldman M, Friedman L, Brandt L, eds. Sleisenger y Fordtran. Enfermedades digestivas y hepáticas. 10ed. Barcelona: Elsevier; 2016. p. 1332-52.

  12. Hassan MA, Osman MS, Ogurtsov PP. Epidemiology of viral hepatitis in Somalia: Systematic review and meta-analysis study. World J Gastroenterol. 2018;24(34):3927-57. PubMed:PMID:30228786

  13. Pawlotsky JM. Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. Gastroenterology. 2015;148(3):468-79. PubMed:PMID:25576860

  14. Andrews J1, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck Y, et al. Grade guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-25.

  15. Gigi E, Raptopoulou M, Kalogeridis A, Masiou S, Orphanou E, Vrettou E, et al. Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease. J Viral Hepat.2008;15(2):145-54.

  16. Sobue S, Nomura T, Ishikawa T, Ito S, Saso K, Ohara H, et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J Gastroenterol. 2001;36(8):544-51.

  17. Castéra L, Sebastiani G, Le Bail B, de Lédinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol. 2010;52(2):191-8.

  18. LLanio R. Atlas en colores de laparoscopia. 3ed. La Habana: Editorial Ciencias Médicas;1991.

  19. Zanchet MV, Silva LL, Matias JE, Coelho JC. Post-reperfusion liver biopsy and its value in predicting mortality and its value in predicting mortality and graft disfunction after liver transplantation. Arq Bras Cir Dig. 2016;29(3):189-93. PubMed:PMID:27759784

  20. Moreira VF, Garrido E. Elastografía hepática (Fibroscan®) en hepatología. Rev esp enferm dig. 2013 [acceso: 14/01/2017];105(4). Disponible en: http://scielo.isciii.es/ scielo.php?script=sci_arttext&pid=S1130-01082013000400011&lng=en&nrm=iso&tlng= esPavlov CS

  21. Casazza G, Nikolova D, Arús E, Rivera L, Fernández A, Infante M, et al. Tratamiento de la hepatitis crónica C con interferón alfa 2b recombinante: Ensayo clínico controlado aleatorizado. Rev Cubana Med. 2000 [acceso: 14/05/2017];39(1):12-20. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232000000100003&lng =es&nrm=iso&tlng=es

  22. Arús E, Rivera L, Infante M, Pérez M, Soto G, Gra B, et al. Tratamiento de la hepatitis viral aguda c con interferón alfa 2b recombinante: Ensayo clínico. Rev cubana med. 2000 [acceso: 14/05/2017];39(1):21-9. Disponible en: http://scielo.sld.cu/scielo.php? script=sci_arttext&pid=S0034-75232000000100004&lng= es&nrm=iso&tlng=es

  23. Castañeda C, García E, Grá B, Nodarse-Cuní H, García W, Andrade M, et al. Interferon alfa 2b treatment decreases histological activity in children with chronic hepatitis B. Acta Gastroenterol Latinoam. 2002;32(1):35-42.

  24. Nodarse H, López PA. Interferón alfa-2b cubano. Treinta años como un medicamento eficaz y seguro. Biotecnol Apl. 2017[acceso: 14/12/2017];34(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522017000100002

  25. Dorta Z, Castellanos M, Nodarse H, Arus E, Pérez F, González L. Tolerancia del tratamiento con interferon estandar y ribavirina en pacientes cirroticos por virus de la hepatitis C. Rev Cubana Med. 2010 [acceso: 19/07/2017];49(2):1-10. Disponible en: http://scielo.sld.cu/pdf/med/v49n2/med01210.pdf

  26. Sánchez Y, Arús E, Gra B, López P, Nodarse H. Interferón alfa 2b recombinante más ribavirina en el tratamiento de la hepatitis crónica C. Rev Cubana Med. 2010 [acceso: 14/07/2017];49(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid= S0034-75232010000200002

  27. Sánchez Y, Arús E, Gra B, López P, Nodarse H. Safety of recombinant interferon alpha 2b plus ribavirin in chronic hepatitis C. Rev Cubana Farm. 2011 [acceso: 15/07/02017];45(1):34-43. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_ arttext&pid= S0034-75152011000100004

  28. Nodarse H, Arus E, Riviera LL, Perez M, Samanda M, García WO, et al. Interferón alfa-2b y ribavirina como tratamiento combinado para la hepatitis C crónica en Cuba: Programa Nacional. Biotecnol Apl. 2012 [acceso: 22/07/2017];29(3):184-88. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1027-28522012000300005&lng= es&nrm=iso&tlng=es

  29. Castellanos M, González A, Nodarse H, Calzadilla L, Martínez Y, Sánchez YA, et al. Estudio clínico abierto, no controlado para la evaluación de la seguridad y eficacia del interferón alfa 2b pegilado PEG-Heberon® más ribavirina para el tratamiento de la infección crónica por el virus de la hepatitis C en pacientes cubanos. Biotecnol. 2015 [acceso: 19/08/2017];32(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid= S1027-28522015000400001

  30. Mishra P, Florian J, Qi K, Zeng W, Naeger LK, Donaldson E, et al. FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin. Gastroenterology. 2014;147(6):1196-200. PubMed:PMID:25449024

  31. Dieterich D, Bacon B, Flamm S, Kowdley K, Milligan S, Tsai N, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network - Academic and community treatment of a real-world, heterogeneous population. Hepatology. 2014 [acceso: 15/05/2018];60:220A. Disponible en: http://www.natap.org/2014/AASLD/AASLD_09.htm

  32. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493-505. PubMed: PMID:26754432.

  33. Younossi ZM, Stepanova M, Feld J, Zeuzem S, Jacobson I, Agarwal K, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016;65(1):33-9. PubMed: PMID:26956698

  34. Lawitz E, Sulkowski MS, Ghalib R, Rodríguez M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756-65. PubMed: PMID:25078309

  35. Sulkowski MS, Gardiner DF, Rodríguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.N Engl J Med. 2014;370(3):211-21. PubMed: PMID:24428467

  36. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368(20):1907-17.

  37. Guías de Práctica Clínica. Recomendaciones de la ESLA para el tratamiento de la Hepatitis C. 2015[acceso: 14/02/2017]. Disponible en: http://www.easl.eu/medias/cpg/HCV-recommendations/Spanish-report.pdf

  38. Investigadores de la Universidad de Paris, Sylvie Deuffic-Burban Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018 [acceso: 14/01/2017];69:785-92. Disponible en: http://dx.doi.org/10.1016/j.jhelp.2018.05.027




2020     |     www.medigraphic.com